| Prev Close: | 46.44 |
|---|---|
| Open: | 46.60 |
| Bid: | 46.79 x 200 |
| Ask: | 46.87 x 8200 |
| 1y Target Est: | 45.69 |
| Beta: | 0.01 |
| Next Earnings Date: | 22-Jul-13 |
| Day's Range: | 46.46 - 47.00 |
|---|---|
| 52wk Range: | 30.64 - 49.57 |
| Volume: | 7,155,486 |
| Avg Vol (3m): | 11,228,100 |
| Market Cap: | 76.95B |
| P/E (ttm): | 53.06 |
| EPS (ttm): | 0.88 |
| Div & Yield: | 1.40 (3.00%) |
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- Final Glance: Pharmaceuticals companiesAP(Tue, Jun 18)
- Midday Glance: Pharmaceuticals companiesAP(Tue, Jun 18)
- The Best Healthcare Betat Motley Fool(Tue, Jun 18)
- Early Glance: Pharmaceuticals companiesAP(Tue, Jun 18)
- Supreme Court Permits Antitrust Scrutiny Of Pharma Settlementsat Forbes(Tue, Jun 18)
- Bristol-Myers Squibb Grants Help K-12 Educators Bring Science to Life and Help Students Explore Their Interests in the Sciences and Science-Based CareersBusiness Wire(Tue, Jun 18)
- Where Is Biotechnology's Next 'Anti-PD-1'?at Seeking Alpha(Tue, Jun 18)
- Arnold & Porter, Skadden, Cravath, Willkie: Business of Lawat Bloomberg(Tue, Jun 18)
- Drugmakers Opened to ‘Pay for Delay’ Suits by High Courtat Bloomberg(Mon, Jun 17)
- Simcere Ties Up with Bristol-MyersZacks(Mon, Jun 17)
- Can Cempra Beat The Superbugs?at Seeking Alpha(Mon, Jun 17)
- J&J: Adding Another Pearl to its Acquisition Necklaceat Wall St. Cheat Sheet(Mon, Jun 17)
- Data on BMY/ AbbVie's elotuzumabZacks(Mon, Jun 17)
- Cramer: A 'Nightmare Scenario' for Bulls and Bearsat CNBC(Mon, Jun 17)
- Gilead's Potential Megablockbuster Raises the Barat Motley Fool(Mon, Jun 17)
Press Releases
- Bristol-Myers Squibb Grants Help K-12 Educators Bring Science to Life and Help Students Explore Their Interests in the Sciences and Science-Based CareersBusiness Wire(Tue, Jun 18)
- Litigation Settlements, Data Compliance Reviews, and Clinical Trials Pave Way for Solid Footing in Healthcare - Research Report on Pfizer, Merck, Bristol-Myers Squibb, Keryx and Pacira PharmaceuticalsPR Newswire(Mon, Jun 17)
- Bristol-Myers Squibb and AbbVie Announce Progression-Free Survival Data from Phase 2 Open-Label Study of Investigational Agent Elotuzumab in Combination with Lenalidimide and Dexamethasone in Previously-Treated Multiple MyelomaBusiness Wire(Sat, Jun 15)
Reports
- Bristol-Myers Squibb CompanyDatamonitor(Jun 18)
- BMY: Due Diligence Review: Forensic Earnings and ValuationNew Constructs, LLC(Jun 18)
- Thomson Reuters Stock Report - BRISTOL-MYERS SQUIBB COMPANY (BMY-N)Thomson Reuters Stock Report(Jun 18)